Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05284253
Other study ID # NorthernODD
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 1, 2024
Est. completion date October 30, 2024

Study information

Verified date January 2024
Source Northern Orthopaedic Division, Denmark
Contact Sten Rasmussen, PhD
Phone 25520462
Email sten@dcm.aau.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators hypothesize gold is inert and thereby there is no pure-gold allergy. The primary aim of this study is to measure the prevalence of allergy to metallic pure gold microparticles and allergy to GSTS.


Description:

TRUE test panel which includes gold sodium thiosulphate (GSTS), 1 % w/v in petrolatum, and gold microparticles, 20-micron diameter, 1 % w/v in petrolatum, will be added added to the baseline series. It will be applied to the upper back of healthy adults in aluminum Finn Chamber for 48 hours. Clinical evaluation will be performed 24 hours after removal the test according to standard procedures for evaluation of epi-cutaneous challenging (Johansen 2015).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date October 30, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients with chronic dermatitis Exclusion Criteria: - age < 18

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Gold microparticles
Metallic gold microparticles, 20-micron diameter, 1 % w/v in petrolatum
Gold thiosulphate
Gold Sodium Thio Sulphate, 1 % w/v in petrolatum

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Northern Orthopaedic Division, Denmark Aalborg University

Outcome

Type Measure Description Time frame Safety issue
Primary Patch test Test materials will be applied on the upper back of the volunteers in aluminium Finn Chambers for 48 hours. Clinical evaluation will be performed 24 hours after removal of the test substances according to standard procedures for evaluation of epicutaneous challenging according to criteria of ICDRG (International Contact Dermatitis Research Group) (Johansen 2015). Reactions: doubtfull, faint macular erythema only; weak positive reaction, erythema, infiltration papules; strong positive reaction, erythema, infiltration, papular, vesicles; erythema positive reaction, intense erythema, infiltration and coalescing vesicles; negative reaction; irritant reaction; not tested 72 hours
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04058743 - Nickel Sensitivity N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Active, not recruiting NCT05605795 - Investigation of Cross-allergies Between Cefazolin and Amoxicillin With Skin Tests and Provocation Test
Recruiting NCT06065137 - Standardised Drug Provocation Testing in Perioperative Hypersensitivity N/A
Completed NCT04510376 - Allergy Potential of Omeza Collagen Matrix in Human Subjects Using the Skin Prick Method N/A
Completed NCT05185479 - Analysis of Adverse Events in Anesthesia Using Artificial Intelligence
Recruiting NCT05185362 - Epidemiology of Pecan Nut Allergy
Completed NCT03525496 - Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents
Completed NCT03489694 - Repeatability and Reproducibility of Skin Test Endpoint Titration
Completed NCT03942692 - What is the Allergy Follow-up for Children After Anaphylactic Reaction? AFCAR : Allergy Follow-up for Children After Anaphylactic Reaction
Enrolling by invitation NCT05670756 - Preoperative Survey to Evaluate Patient Allergy
Recruiting NCT05462444 - Development of Personalized Balanced Nutrition Concept Through an IT Platform
Completed NCT03157505 - Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis Phase 3
Completed NCT01436617 - Assessing the Value of a Dosage of Anti-cetuximab in the Therapeutic Management of Patients With Colon Cancer or Upper Aero-digestive Tract and Candidates for Treatment With Cetuximab Phase 2
Not yet recruiting NCT05533385 - Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation. N/A
Not yet recruiting NCT05532566 - Quercus Ilex and Quercus Robur Allergen Extracts Standardisation N/A
Recruiting NCT06011603 - Prineo Sensitivity Dressing Study Phase 4
Completed NCT04761822 - COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations Phase 2
Recruiting NCT05367531 - Assessment of Injectable Medication Platforms N/A